The PI3Kδ inhibitor idelalisib suppresses liver and lung cellular respiration

Idelalisib (an inhibitor of phosphatidylinositol-3-kinase-delta) is approved for treatment of B-cell malignancies, with a Boxed Warning concerning potentially fatal hepatic, lung, and intestinal toxicities. The mechanisms of these tissue-specific adverse events have yet to be elucidated. This in vit...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Int J Physiol Pathophysiol Pharmacol
Autores principales: Hammadi, Suleiman Al, Almarzooqi, Saeeda, Abdul-Kader, Hidaya Mohammed, Saraswathiamma, Dhanya, Souid, Abdul-Kader
Formato: Artigo
Lenguaje:Inglês
Publicado: e-Century Publishing Corporation 2015
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4697667/
https://ncbi.nlm.nih.gov/pubmed/26823960
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares